15 January 2019

Commissioned research: AlzeCure Pharma

OUTPERFORM: We initiate coverage on AlzeCure Pharma with a step wise valuation approach. For 2019, we see a reasonable valuation range between SEK17-20 per share suggesting 102-138% upside to the current share price. For 2020, we see a range between SEK29-34 per share suggesting 245-305% upside to the current share price.

First-in-class tablets, team with significant big pharma experience
AlzeCure Pharma is a Swedish-based pharmaceutical company with potentially first-in-class proprietary and novel targeted small molecule (tablets) candidates for neurodegenerative diseases with a primary target on Alzheimer’s Disease (AD). AlzeCure’s management team has extensive big pharma experience, and formed an integral part of AstraZeneca’s CNS department.

Click here to download report

Marketing material commissioned by AlzeCure Pharma